Phase2 Clinical Trial of Hepatocyte Growth Factor Gene Therapy for Primary Lymphedema
Phase 2
- Conditions
- Primary Lymphedema
- Registration Number
- JPRN-UMIN000033159
- Lead Sponsor
- Asahikawa medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1, stage 3 by ISL classification 2, aplasia or hyperplasia 3, another hereditary 4, malignancy 5, cellulitis at the time of registration 6, received the operation within 90 days 7, severe disease of liver, kidney, heart, or blood 8, alcohol dependence 9, registration of another clinical trials within 90 days 10, the pregnant 11, received the treatment of another gene therapy 12, unfitness patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of Life (SF-36 and LYMQOL) at 12 and 24 week
- Secondary Outcome Measures
Name Time Method